WO2000012482A3 - Composes chimiques iii - Google Patents

Composes chimiques iii Download PDF

Info

Publication number
WO2000012482A3
WO2000012482A3 PCT/GB1999/002883 GB9902883W WO0012482A3 WO 2000012482 A3 WO2000012482 A3 WO 2000012482A3 GB 9902883 W GB9902883 W GB 9902883W WO 0012482 A3 WO0012482 A3 WO 0012482A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
alkyl
compounds
disorders
ch2ch
Prior art date
Application number
PCT/GB1999/002883
Other languages
English (en)
Other versions
WO2000012482A2 (fr
Inventor
David Reginald Adams
Jonathan Richard Anthon Roffey
Claire Elizabeth Dawson
Original Assignee
Cerebrus Pharm Ltd
David Reginald Adams
Jonathan Richard Anthon Roffey
Claire Elizabeth Dawson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerebrus Pharm Ltd, David Reginald Adams, Jonathan Richard Anthon Roffey, Claire Elizabeth Dawson filed Critical Cerebrus Pharm Ltd
Priority to AU56374/99A priority Critical patent/AU5637499A/en
Publication of WO2000012482A2 publication Critical patent/WO2000012482A2/fr
Publication of WO2000012482A3 publication Critical patent/WO2000012482A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de la formule (I) destiné à s'utiliser pour un traitement. Dans la formule selon l'invention, R1 et R2 sont indépendamment sélectionnés dans le groupe formé par hydrogène et alkyle; R3 représente un alkyle; R4 à R7 sont indépendamment sélectionnés dans le groupe formé par hydrogène, halogène, hydroxy, alkyle, aryle, amino, monoalkylamino, dialkylamino, alcoxy, aryloxy, alkylthio, arylthio, arylsulfoxyle, arylsulfonyle, alkylsulfoxyle, alkylsulfonyle, nitro, cyano, carboxaldéhyde, alkylcarbonyle, arylcarbonyle, aminocarbonyle, monoalkylaminocarbonyle, dialkylaminocarbonyle, alcoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino et dialkylaminocarbonylamino, au moins un des éléments de R4 à R7 représentant un substituant autre que l'hydrogène; et R8 est sélectionné dans le groupe formé par hydrogène et alkyle. L'invention concerne également des sels et promédicaments de ce composé acceptables du point de vue pharmaceutique, autres que les composés dans lesquels R1 représente un hydrogène et R2 représente -H2CH(OH)-Ar; et autres que les composés dans lesquels R2 représente H et R1 représente -H2CH(OH)-Ar, Ar désignant 3-halophényle ou 3-trifluorométhylphényle. L'invention concerne en outre l'utilisation de ces composés pour une thérapie, notamment pour le traitement de troubles du système nerveux central; de lésions du système nerveux central; de troubles cardiovasculaires; de troubles gastro-intestinaux; du diabète insipide et de l'apnée du sommeil et particulièrement pour le traitement de l'obésité. L'invention concerne enfin de nouveaux composés chimiques de la formule (I).
PCT/GB1999/002883 1998-09-01 1999-09-01 Composes chimiques iii WO2000012482A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56374/99A AU5637499A (en) 1998-09-01 1999-09-01 Chemical compounds iii

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9819020.0 1998-09-01
GBGB9819020.0A GB9819020D0 (en) 1998-09-01 1998-09-01 Chemical compounds III

Publications (2)

Publication Number Publication Date
WO2000012482A2 WO2000012482A2 (fr) 2000-03-09
WO2000012482A3 true WO2000012482A3 (fr) 2000-05-25

Family

ID=10838155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002883 WO2000012482A2 (fr) 1998-09-01 1999-09-01 Composes chimiques iii

Country Status (3)

Country Link
AU (1) AU5637499A (fr)
GB (1) GB9819020D0 (fr)
WO (1) WO2000012482A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
PL365422A1 (en) * 2000-03-17 2005-01-10 Alcon, Inc. 5-hydroxy indazole derivatives for treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
CA2449899C (fr) 2000-11-20 2010-04-06 Biovitrum Ab Composes de piperazinylpyrazines utilises comme antagonistes du recepteur de la serotonine 5-ht2
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
CA2432122A1 (fr) 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Ligands d'agoniste et d'antagoniste du recepteur de serotonine a substitution aryle et aminoaryle
CN100484933C (zh) 2002-06-19 2009-05-06 比奥维特罗姆股份公开公司 新的吡嗪化合物及其在制备用于治疗与5-羟色胺相关的疾病的药物中的用途
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
EP2248524A3 (fr) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci
AU2005300045A1 (en) 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
WO2006103511A1 (fr) 2005-03-31 2006-10-05 Pfizer Products Inc. Derives de cyclopentapyridine et de tetrahydroquinoline
EP2742936A1 (fr) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Composé hétérocyclique condensé et son utilisation
EP2789338A3 (fr) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Dérivé de pyridine condensé et son utilisation
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
EP3733204A4 (fr) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited Agent thérapeutique pour incontinence urinaire de stress et incontinence fécale

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494774A1 (fr) * 1991-01-11 1992-07-15 MERCK SHARP & DOHME LTD. Composés hétéroaromatiques à 5 chaînons substitués par l'indazole
JPH08165276A (ja) * 1994-12-14 1996-06-25 Dainippon Pharmaceut Co Ltd ２−アルキルアミノ−１−フェニルエタノール誘導体
WO1998030548A1 (fr) * 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. AGONISTES DU RECEPTEUR 5-HT2c ET DERIVES D'AMINOALKYLINDAZOLE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494774A1 (fr) * 1991-01-11 1992-07-15 MERCK SHARP & DOHME LTD. Composés hétéroaromatiques à 5 chaînons substitués par l'indazole
JPH08165276A (ja) * 1994-12-14 1996-06-25 Dainippon Pharmaceut Co Ltd ２−アルキルアミノ−１−フェニルエタノール誘導体
WO1998030548A1 (fr) * 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. AGONISTES DU RECEPTEUR 5-HT2c ET DERIVES D'AMINOALKYLINDAZOLE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTA PHARM. SUEC. (1974), 11(2), 196-200 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CARNMALM, BERNT ET AL: "Antidepressant agents. III. Aza analogs of etryptamine", XP002133733, retrieved from STN Database accession no. 81:37512 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KATO, SHIRO ET AL: "Preparation of 2-alkylamino-1-phenylethanol derivatives as.beta.3-adrenergic agents", XP002133734, retrieved from STN Database accession no. 125:195419 *

Also Published As

Publication number Publication date
WO2000012482A2 (fr) 2000-03-09
AU5637499A (en) 2000-03-21
GB9819020D0 (en) 1998-10-28

Similar Documents

Publication Publication Date Title
WO2000012482A3 (fr) Composes chimiques iii
CA2341991A1 (fr) Pyrroloindoles, pyridoindoles et azepinoindoles comme agonistes de 5-ht2c
WO2000012481A3 (fr) Composes chimiques iv
AU5637799A (en) Pyrroloquinolines for treatment of obesity
WO2000017170A3 (fr) Composes chimiques viii
GB9902047D0 (en) Chemical compounds XI
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
YU69902A (sh) Novi derivati piperazina
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
AR029815A1 (es) Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento
TW200635930A (en) Bicyclic pyrrole derivatives
EP1447405A4 (fr) Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
WO2002008219A3 (fr) Nouvelles 2-adamantylethylamines et leur utilisation dans le traitement d'etats generalement associes a des anomalies de la transmission glutamatergique
AU3626895A (en) Quinazolinone pharmaceuticals and use thereof
WO2005053702A3 (fr) Agents anti-inflammatoires
WO2008087650A3 (fr) Composition et procédé pour traiter ou prévenir une fibrose des muscles squelettiques
NZ516194A (en) Optically active pyrrolopyridazine compounds
AU2292199A (en) Adamantanecarboximidamide derivatives and their use as nmda antagonists
MX2007007485A (es) Derivados de cromano y usos de los mismos en el tratamiento de trastornos del sistema nervioso central.
WO2001007023A3 (fr) Composes chimiques - ii
WO2001005384A3 (fr) Composes
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase